Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + Fulvestrant in HR+, HER2-, PIK3CA Mutated Advanced Breast Cancer in Japan
NCT04524000Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2021
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in breast cancer, sponsored by Novartis. Started Jan 2021; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04524000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524000.